Drug Patch Manufacturers Can Skip Quality By Design Approach, FDA Says

Final guidance softens a recommendation that manufacturers of transdermal and transmucosal drug delivery systems and topical patches use a Quality by Design approach.

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Archive

More from Pink Sheet